**Table 1. Clinical data of the patients with hormonally inactive adenoma and the patients of adrenocortical cancer depending on their response to polychemotherapy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter, Ме [Q1; Q3]** | **ACC responders to PCT (n = 23)** | **ACC non-responders to PCT (n = 7)** | **Control group (HIA) (n = 25)** | **P value** |
| **(1)** | **(2)** | **(C)** |
| Age, years | 44 [35; 61] | 43 [29; 61] | 50 [40; 61] | p(1–C) = 0.12p(1–2) = 0.46p(2–C) = 0.11 |
| M:F, N | 6:17 | 2:5 | 7:18 |  |
| Tumor size, mm | 89 [60; 99] | 105 [75; 215] | 25 [21; 30] | p(1–C) = 0.0001p(1–2) = 0.39p(2–C) = 0.001 |
| Кi-67, % | 22 [13; 46] | 35 [27; 50] | – | p(1–2) = 0.85 |
| L.M. Weiss score | 4 [4; 8] | 7 [6; 9] | 0 | p(1–2) = 0.45 |

ACC, adrenocortical cancer; F, female patients; HIA, hormonally inactive adenoma; M, male patients; PCT, polychemotherapy

**Table 2. Urine excretion of the main biomarkers of adrenocortical cancer after surgery and polychemotherapy (assessed by gas chromatography-mass spectrometry)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Steroid, Ме [Q1; Q3], mcg/24h** | **ACC responders to PCT (n = 23)** | **ACC non-responders to PCT (n = 7)** | **Control group (HIA) (n = 25)** | **P value** |
| **(1)** | **(2)** | **(C)** |
| Etiocholanolone (Et) | 195 [81; 539] | 1416 [1258; 3790]\* | 589 [360; 720] | p(1–C) = 0.004p(2–C) = 0.005 |
| Androstendiol-17β (dA2-17β) | 41 [22; 121] | 291 [129; 434]\*\* | 87 [45; 117] | p(1–C) = 0.23р(2–C) = 0.005 |
| Dehydroepiandrosterone (DHEA) | 109 [23; 311] | 1938 [1573; 8473]\* | 122 [47; 260] | p(1–C) = 0.95p(2–C) = 0.0004 |
| 16α-ОН-DHEA | 231 [85; 486] | 3200 [704; 11600]\* | 142 [36; 278] | p(1–C) = 0.29p(2–C) = 0.0007 |
| 16-oxo-androstendiol (16-охо-dA2) | 38 [11; 92] | 279 [214; 436]\* | 25 [15; 45] | p(1–C) = 0.80p(2–C) = 0.012 |
| Androstentriol (dA3) | 111 [54; 333] | 2193 [546; 13047]\* | 142 [96; 279] | p(1–C) = 0.47p(2–C) = 0.002 |
| 17-ОН-pregnanolone (17-OHP) | 98 [46; 210] | 723 [184; 1150]\*\* | 197 [104; 267] | p(1–C) = 0.21p(2–C) = 0.029 |
| Pregnanediol (P2) | 179 [73; 495] | 839 [800; 1560]\*\* | 443 [270; 644] | p(1–C) = 0.021p(2–C) = 0.045 |
| Pregnanetriol (P3) | 289 [144; 780] | 1965 [1605; 5223]\* | 635 [553; 812] | p(1–C) = 0.042p(2–C) = 0.013 |
| Pregnenediol (dP2) | 210 [155; 770] | 2455 [1441; 3625]\* | 516 [236; 761] | p(1–C) = 0.099p(2–C) = 0.004 |
| 3α,16,20-pregnenetriol (3α,16,20-dP3) | 156 [37; 395] | 1068 [570; 1137]\* | 136 [79; 210] | p(1–C) = 0.73p(2–C) = 0.005 |
| 3α,17,20-pregnenetriol (dP3-3α) | 205 [125; 500] | 4994 [1716; 10532]\* | 168 [131; 276] | p(1–C) = 0.23p(2–C) = 0.0002 |
| Tetrahydro-11-deoxycortisol (ТНS) | 110 [38; 359] | 1310 [1076; 2220]\* | 78 [35; 111] | p(1–C) = 0.11p(2–C) = 0.0006 |
| 3β,16,20-pregnentriol (3β,16,20-dP3) | 40 [27; 90] | 617 [378; 681]\* | Not found | \_ |

ACC, adrenocortical cancer; HIA, hormonally inactive adenoma; PCT, polychemotherapy

\* р < 0.017, \*\* p < 0.005, significant of the difference between the ACC patients responding and not responding to PCT